ArticleFrontiers in endocrinology2026
Peritoneal neuroendocrine carcinoma of unknown primary with markedly elevated alpha-fetoprotein: a case report.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peritoneal neuroendocrine carcinoma(NEC) is primarily metastatic, with primary cases being exceedingly rare. The relationship between alpha-fetoprotein(AFP) and neuroendocrine carcinoma remains unclear. In this report, we present a patient with peritoneal neuroendocrine carcinoma who exhibited significantly elevated AFP levels. Extensive evaluation revealed no obvious primary site outside the peritoneum; however, occult gastrointestinal origin could not be entirely excluded. The tumor was thus classified as NEC of unknown primary, with a presumed primary peritoneal origin. The findings from this case suggest that markedly elevated AFP may be associated with aggressive tumor behavior and could serve as a potential marker for monitoring disease activity in peritoneal NECs, a hypothesis that warrants further investigation. Case presentation: A 51-year-old man with massive ascites and elevated AFP levels was admitted to the hospital. Liver enhanced magnetic resonance imaging and gastrointestinal endoscopy did not reveal any space-occupying lesions, while abdominal puncture did not detect tumor cells. The patient's whole-body PET-CT revealed extensive peritoneal thickening and increased FDG metabolism. Subsequent laparoscopic exploration revealed numerous nodules and masses of varying sizes with a firm texture in the greater omentum, small intestine surface, mesentery, and parietal peritoneum. Immunohistochemistry of the omentum demonstrated positive results for AE1/AE3, Syn, CgA, and AFP, leading to a final diagnosis of large cell NEC of unknown primary, with a presumed primary peritoneal origin. Due to the presence of multiple peritoneal nodules, radical surgery was not feasible, and EP combined with camrelizumab was initiated. AFP levels showed an overall progressive increase, peaking at 5315 ng/mL on May 25, with a slight subsequent decline to 4948.4 ng/mL on June 20. Unfortunately, the patient discontinued chemotherapy after two cycles due to severe nausea and vomiting; he subsequently succumbed to the disease. Conclusions: We propose the hypothesis that dynamic changes in AFP levels could reflect tumor burden and treatment response in a subset of AFP-producing NECs. However, this hypothesis requires validation in larger cohort studies. It is also important to distinguish its potential role as a monitoring biomarker from an established prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.